Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia – PubMed
In patients treated in a PE, a neutropenic diet did not prevent major infection or death.
Related Articles
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function
Isshiki et al. demonstrate that EZH2 inhibitors re-activate immune synapse functions between B cell lymphomas and T cells, sensitizing lymphomas to T cell immunotherapies. EZH2 inhibition enhances killing…
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
Patients with follicular lymphoma (FL) who progress within 24 months of front-line therapy (POD24) have poor outcomes, but clinical factors predicting earl
POD24 in follicular lymphoma: time to be “wise”
This issue of Blood features valuable new data from Casulo et al1 focusing on an important problem in follicular lymphoma (FL). FL is the most common…
Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19: An International, Randomised, Open-Label Trial
Background: COVID-19 convalescent plasma (CCP) is a treatment option for COVID-19. This study investigated the safety and efficacy of early, very high-titre CCP
Time-Related Biases in Nonrandomized COVID-19–Era Studies Using Real-world Data
The urgent response to the COVID-19 pandemic has highlighted the importance of diverse, real-world data sources, such as electronic health records, insurance claims, and patient…
Survival in Patients With Hematologic Cancers and COVID-19
This cohort study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19.
Iron deficiency resolution and time to resolution in an American health system
Key PointsIn a statewide cohort, time to resolution of iron deficiency was 1.9 years, and 58% of patients did not achieve resolution within 3 years.Greater
Dietary supplement S-adenosyl-L-methionine (AdoMet) effects on plasma homocysteine levels in healthy human subjects: a double-blind, placebo-controlled, randomized clinical trial – PubMed
AdoMet at a daily dose of 800 mg for 4 weeks does not appear to significantly affect Hcy levels in the blood.
Tri-specific Antibody SAR442257 in RRMM and Non- Hodgkin Lymphoma | Fredrik Schjesvold | #ASH24
Fredrik Schjesvold, MD, PhD, discusses a phase 1 trial of a trispecific drug designed to boost T-cell activation in myeloma and lymphoma treatment. While the…
Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms
Leukemia – Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms